PHAXIAM publie aujourd’hui sa trésorerie au 30 juin 2023 et son calendrier financier pour le second semestre 2023.
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
PHAXIAM Therapeutics announces a reverse share split of its shares
PHAXIAM announces the implementation of the reverse share split of the shares composing the Company’s share capital, by decision of the CEO on July 26th, 2023, following the sub-delegation granted by the Board of Directors on June 23rd, 2023, taken in accordance with the 23rd extraordinary resolution of the General Shareholders’ Meeting of June 23rd, 2023.
PHAXIAM Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
PHAXIAM announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will be effective from June 29, 2023.
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
Erytech announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
ERYTECH announces that the Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma
ERYTECH Responds to Akkadian’s Disinformation
The company reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
Erytech announces that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 23, 2023 at 09:30am CEST at the Hôtel Intercontinental, 2 rue Scribe, 75009 Paris (FRANCE).
ERYTECH Announces the availability of the exemption document relating to the proposed combination with Pherecydes
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
Erytech provided a business and financial update for the fourth quarter and full year of 2022.
ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies
ERYTECH and PHERECYDES announced their proposed strategic combination intended to create a global player in extended phage therapy and accelerate the development of a portfolio of drug candidates targeting pathogenic bacteria and potential other indications of high unmet medical needs.
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
Conference call and webcast on Tuesday, November 22, 2022 at 8:30am EST / 02:30pm CEST
ERYTECH Announces Receipt of Nasdaq Notice
Erytech announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC regarding its American Depositary Shares (“ADSs”)
ERYTECH Provides Business and Financial Update for the First Half of 2022
ERYTECH Pharma today provided a business and financial update for the first half of 2022.
ERYTECH Provides Regulatory Update
ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug Administration (FDA).
REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022
ERYTECH Pharma announced that its Annual General Meeting was held on Friday, June 24, 2022.
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2 rue Scribe, 75009 Paris (FRANCE).
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA.
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
ERYTECH Pharma provided a business and financial update at the end of March 2022.
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar
ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the “Autorité des Marchés Financiers” (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC), as well as its 2022 financial calendar.
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent
ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology
The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option for acute lymphoblastic leukemia (ALL) patients with hypersensitivity to PEG-asparaginase
ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society
ERYTECH Pharma announced the presentation of its novel red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society (ERCS), taking place from April 7 to 11, 2022 in Gazzada Schianno, Italy.
ERYTECH to Participate in the Upcoming April Investor Conferences
ERYTECH Pharma today announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings.
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021
ERYTECH Pharma (Nasdaq & Euronext: ERYP) provided a business update and an update on its cash position at the end of December 2021.
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
ERYTECH Pharma announced the allowance of a US patent application covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D), a debilitating rare metabolic disease
ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
ERYTECH Pharma announced the presentation of results of two trials evaluating eryaspase in advanced pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 21, 2022.
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
ERYTECH Pharma announced today their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings
ERYTECH Announces $7.85 Million Registered Direct Offering
ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has entered into a definitive agreement with Armistice, a health-care focused institutional and accredited investor, for the purchase and sale of 769,608 units (“Units”), each Unit consisting of four ordinary shares in the form of American Depositary Shares (each an “ADS”) and three warrants, each to purchase one ordinary share (each a “Warrant”), in a registered direct offering to specified categories of investors, described below. The subscription price for one Unit is $10.20 (€9.04), corresponding to $2.55(€2.26) per ADS and associated 0.75 warrant. Each ADS represents the right to receive one ordinary share, €0.10 nominal value, of the Company. The Warrants have an exercise price of €2.83 ($3.19) per share, will be immediately exercisable upon issuance and will expire two years from the issuance date. The closing of the offering is expected to occur on or about December 20, 2021, subject to satisfaction of customary closing conditions.
ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced a summary of its poster presentation at the 2021 ASH Annual Meeting evaluating GRASPA® (eryaspase) in acute lymphoblastic leukemia (ALL) as well as the acceptance of two abstracts evaluating eryaspase in advanced pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), which will be held January 20-22, 2022, both in San Francisco, CA and virtually.
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the granting of US patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase.
ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET
- Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase; Fast Track designation granted; submission of BLA intended around year-end
- Phase 3 trial in second-line pancreatic cancer did not meet its primary endpoint
- Recommended Phase 2 dose determined from Phase 1 IST in first-line pancreatic cancer of eryaspase with mFOLFIRINOX
- Process to review strategic options and partnering alternatives launched
- Cash and cash equivalents of €38.0 million ($43.9 million) at the end of September 2021
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the acceptance of an abstract with the results of its expanded access program (EAP) evaluating eryaspase in acute lymphoblastic leukemia (ALL) for poster presentation at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting, which will be held from December 11-14, 2021, both in Atlanta, Georgia and virtually.
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
The Paper “Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process” is available in the October 2021 (Volume 11, Issue 10) of Acta Pharmaceutica Sinica B (APSB)
The characterization demonstrated that ERYCAPS® hypotonic dialysis encapsulation process induces some changes to red blood cell (RBC) features without substantially affecting their survival or their capacity to carry therapeutics
ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
In-Person Dates: November 16th-17th • Virtual Dates: November 18th-19th
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its CEO, Gil Beyen, will participate in a fireside chat at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in one-on-one meetings both in-person on Tuesday and Wednesday, November 16th/17th or virtually on Thursday and Friday, November 18th/19th.
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
Management to host Conference Call on Monday, October 25, at 8:30am EDT/ 2:30pm CEST
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced top-line results from its Phase 3 TRYbeCA-1 clinical trial evaluating eryaspase as second-line treatment in 512 patients with metastatic pancreatic cancer. The trial did not meet its primary endpoint of overall survival (OS).
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
- No dose-limiting toxicity (DLT) reported in first two dose cohorts, leading to declaration of the maximum tolerated dose (MTD) at 100 U/kg
- Encouraging clinical activity observed in first patients
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the MTD has been declared in a Phase 1 investigator sponsored clinical trial (IST), named rESPECT, of its lead product candidate eryaspase for the first-line treatment of pancreatic cancer, defining the recommended dose for future clinical trials in this indication at 100 U/kg.
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the company’s participation in one-on-one investor meetings at the HealthTech Innovation Days (HTID) by France Biotech being held in Paris and virtually on October 4th & 5th, 2021.
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed with the Autorité des Marchés Financiers (AMF) its half-year report for the six-month period ended June 30, 2021.
The half-year financial report is available in the Investors section of the Company’s corporate website (www.erytech.com).
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
Conference call and webcast on Tuesday, September 21, 2021 at 8:30am EDT / 2:30pm CET
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the first half of 2021.
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights.
ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th – 15th, 2021.
Webinar on Eryaspase in Pancreatic Cancer

Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and Dr. Marcus Noel, M.D., Georgetown University.
ERYTECH to Participate in the Citi 16th Annual BioPharma Conference
Citi’s 16th Annual BioPharma Conference– September 8 -10, 2021
Cambridge, MA (U.S.) and Lyon (France), August 30, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its participation in the Citi 16th Annual BioPharma Conference and invites investors to join virtually via one-on-one meetings.
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
Webinar on Wednesday, September 1st @ 10am ET/4pm CET
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today it will host a key opinion leader webinar on its lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, on Wednesday, September 1, 2021 at 10:00am Eastern Time. The webinar will feature a presentation by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and Dr. Marcus Noel, M.D., Georgetown University.
ERYTECH reçoit la désignation Fast Track de la FDA américaine pour eryaspase dans le traitement de la LAL hypersensible
ERYTECH Pharma (Nasdaq & Euronext : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, annonce aujourd’hui que la Food and Drug Administration (FDA) américaine a accordé à eryaspase la désignation « Fast Track » pour le traitement des patients atteints de leucémie aiguë lymphoblastique (LAL) qui ont développé des réactions d’hypersensibilité à l’asparaginase pégylée dérivée d’E. coli (PEG-ASNase).
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9th.
ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration (FDA) for eryaspase in hypersensitive acute lymphoblastic leukemia (ALL) patients following feedback from the agency in a pre-BLA meeting.
REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021
Lyon (France), June 25, 2021 – ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) announced that its 2021 Annual General Meeting was held in Lyon on Friday, June 25, 2021.
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its partipation in the following investor conferences in the month of June.
ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021
Live webcast of the Shareholders’ Meeting
Availability of the preparatory documents for the Shareholders’ Meeting
Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 25, 2021, and also the associated details.
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
Conference call and webcast on Wednesday, May 5, 2021 at 8:30am EST/ 2:30pm CET
- TRYbeCA-1, Phase 3 clinical trial in 2nd line pancreatic cancer, fully enrolled, and on track for final results in Q4 2021
- Pre-BLA meeting with FDA requested to discuss the potential submission of a Biologics License Application (BLA) for eryaspase in hypersensitive ALL in the second half of this year
- First dose cohort in Phase 1 Investigator Sponsored Trial (IST) in 1st line pancreatic cancer completed with no dose limiting toxicity; encouraging signs of clinical activity observed
- Cash and cash equivalents of €37.4 million ($43.9 million) at the end of March 2021
- Successful registered direct round of $ 30 million with specialized healthcare investors in April 2021
- Cash horizon extended to mid 2022, beyond anticipated key catalysts
ERYTECH Announces $30.0 Million Registered Direct Offering
ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has entered into definitive agreements with several health-care focused institutional and accredited investors for the purchase and sale of 1,034,483 units (“Units”), each Unit consisting of four ordinary shares in the form of American Depositary Shares (each an “ADS”) and three warrants, each to purchase one ordinary share (each a “Warrant”), in a registered direct offering to specified categories of investors, described below. The subscription price for one Unit is $29.00 (€24.03), corresponding to $7.25 (€6.01) per ADS and associated 0.75 warrant. Each ADS represents the right to receive one ordinary share, €0.10 nominal value, of the Company. The Warrants have an exercise price of €7.50 ($9.05) per share, will be immediately exercisable upon issuance and will expire two years from the issuance date. The closing of the offering is expected to occur on or about May 4, 2021, subject to satisfaction of customary closing conditions.
ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call
Publication of Q1 2021 results on 4 May 2021 after market close
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its cash position at the end of the first quarter 2021 and that it will host its 2021 first quarter conference call and webcast on Wednesday, May 5, 2021, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initiation of the process of seeking marketing approval from the U.S. Food and Drug Administration (US FDA) for its lead product candidate eryaspase in patients with acute lymphoblastic leukemia (ALL) who developed hypersensitivity reactions to PEG-asparaginase based on the positive results of the NOPHO-sponsored Phase 2 clinical trial.
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment of the first treatment cohort and the escalation to the next and potentially final dose level in a Phase 1 investigator sponsored clinical trial (IST), named rESPECT, of its lead product candidate eryaspase for the first-line treatment of pancreatic cancer.
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in the following conferences in the month of April and engage in select one-on-one investor meetings alongside members of the senior management.
ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2020 Universal Registration Document for the year ended December 31, 2020, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC).
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
Conference call and webcast on Tuesday, March 9, 2021 at 8:30am EST/ 2:30pm CET
- Strong execution and achievement of key milestones in challenging year 2020
- Four clinical programs with lead product candidate eryaspase expected to report results and/or regulatory milestones in 2021. Two major catalysts:
- TRYBeCA-1, Phase 3 in 2L pancreatic cancer, expected to report final results in Q4 2021
- Update on potential path to BLA in hypersensitive ALL, expected in 1H 2021
- Cash and cash equivalents of €44.4 million ($54.4 million) at the end of December 2020
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2020.
ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2020 conference call and webcast on Tuesday, March 9, 2021, at 2:30 PM CET/8:30 AM ET to discuss operational highlights.
ERYTECH to Participate in Upcoming Virtual Investor Conferences in March
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the following conferences in the month of March and participate in select one-on-one investor meetings alongside members of the senior management.
ERYTECH to Present at the 2021 BIO CEO & Investor Conference
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings. The conference will be held virtually this year with all participants joining remotely from February 16 to 18, 2021.
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that TRYbeCA-1, a Phase 3 clinical trial evaluating eryaspase in second-line pancreatic cancer, will continue without modification following a planned interim superiority analysis conducted by an Independent Data Monitoring Committee (IDMC).
ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided an update on main achievements in 2020 and key expected milestones for 2021, and reported its end of year 2020 cash position.
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the first patient enrolled in a Phase 1 investigator sponsored trial (IST), named rESPECT, of its lead product eryaspase for the first-line treatment of pancreatic cancer.
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C. Wainwright Virtual BioConnect 2021 in a pre-recorded corporate overview presentation.
ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6th at 9am EST /2pm GMT /3pm CET. The format will be a virtual presentation with the opportunity for Q&A at the conclusion.
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.
ERYTECH to Present at the JMP Securities Hematology Summit
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the JMP Securities Hematology Summit Tuesday December 15th at 1:30pm EST /06:30pm GMT /7:30pm CET. The format will be a “fireside chat” discussion hosted by JMP Securities’ Reni Benjamin.
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
Webcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET
The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients, which were presented by Dr. Line Stensig Lynggaard at the 62nd American Society of Hematology (ASH) Annual Meeting yesterday. In a webcast later today, Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, and Principal Investigator of the trial, will comment on the data and be available for Q&A.
ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces a webcast scheduled for investors to discuss the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients.
ERYTECH to Present at Jefferies Virtual Healthcare Conference
ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12:00pm EST / 05:00pm GMT / 6:00pm CET on November 18, 2020.
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020
Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update.
- TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer
- NOPHO-sponsored Phase 2 trial in acute lymphoblastic leukemia
- Appointment of Dr. Stewart Craig as Chief Technical Officer
- Cash and cash equivalents of €40.5 million ($47.5 million) at the end of September 2020
- €10 million ($11.7 million) in non-dilutive financing secured in the form of state-guaranteed loans
ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces that an abstract detailing results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients, has been selected for oral presentation at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8. A second abstract detailing population pharmacokinetics of eryaspase in ALL or pancreatic adenocarcinoma patients has been accepted for a poster presentation at the meeting.
ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that it has received financing approvals from Bpifrance and Société Générale for a total of €10 million in the form of State-Guaranteed Loans (Prêts Garantis par l’Etat, or PGE in France) in the context of the COVID-19 pandemic.
ERYTECH to Host Third Quarter 2020 Conference Call and Business Update on November 6, 2020
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2020 conference call
and webcast on Friday, November 6, 2020, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH Appoints Stewart Craig as Chief Technical Officer
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appointment of Dr. Stewart Craig as its Chief Technical Officer (CTO) and member of the executive team. Dr. Craig brings 35 years of experience in the development, manufacturing, technical operations, quality systems and regulatory affairs for complex biologics and cell & gene therapies worldwide.
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020
Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update.
ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen
ERYTECH Pharma (Euronext Paris : ERYP – Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the “Company”), today announced the implementation of an at-the-market program allowing the Company to issue and sell ordinary shares in the form of American Depositary Shares (“ADSs”), to eligible investors at market prices, with aggregate gross sales proceeds of up to $30,000,000 (subject to a regulatory limit of 20% dilution), from time to time, pursuant to the terms of a sales agreement with Cowen acting as sales agent.
ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2020 conference call and webcast on Tuesday, September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting.
ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 26, 2020.
ERYTECH extends its cash horizon by implementing a convertible bond financing
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic substances in red blood cells, announced today the signature of an agreement allowing the issuance for the benefit of Luxembourg-based European High Growth Opportunities Securitization Fund, represented by its asset manager European High Growth Opportunities Manco SA (entities related to Alpha Blue Ocean) of convertible notes whereby the Investor committed to subscribe up to a maximum of EUR 60 million in the event of conversion of all the notes, subject to the regulatory limit of 20% dilution, currently representing approximately EUR 30 million, unless further authorized. The notes come with share warrants representing 10% of the nominal amount of the issued notes whose exercise price will reflect a 20% premium over the lowest volume-weighted average daily price of the share over the reference period preceding the issue of the first tranche.
ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia
- Patient enrollment completed; 50 patients in the trial
- Encouraging preliminary results based on interim data
- Unmet medical need confirmed by FDA
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided an update on the ongoing Phase 2 trial, sponsored by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) of eryaspase in second-line acute lymphoblastic leukemia (ALL) patients.
ERYTECH to Participate Fireside Chat at Jefferies Virtual Healthcare Conference
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil BEYEN, Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 08:30 am ET.
ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting.
ERYTECH’S COMBINED SHAREHOLDERS’ MEETING
Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting
Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 26, 2020, and also the associated details.
ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020
TRYbeCA-1 Phase 3 Trial:
- More than 75% of the planned~500 patients enrolled
- Fast-Drack designation granted by U.S. FDA
- Trial to continue as planned after third independent safety review
- Interim superiority analysis expected around year-end and final analysis in 2H of 2021
Cash position of € 58.6 million ($64.6 million) at the end of the first quarter 2020
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update
ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework of the EU Horizon 2020 program.
ERYTECH to Host on May 7, 2020 First Quarter Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2020 first quarter conference call and webcast on Wednesday, May 7, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track Designation for the development of a second-line treatment of patients with metastatic pancreatic cancer.
ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today provided an update on the pivotal Phase 3 clinical trial for advanced metastatic pancreatic cancer (TRYbeCA-1), which is evaluating the efficacy and safety of ERYTECH’s lead product candidate eryaspase in combination with chemotherapy as second-line therapy.
ERYTECH Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2019 Universal Registration Document for the year ended December 31, 2019, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission (SEC).
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2019
Conference call and webcast on Tuesday, March 17 at 1:30 pm CET/8:30 am ET
- More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA-1 Phase 3 clinical trial
- Cash position of €73.2 million ($82.2 million) at the end of 2019
ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the appointment of Melanie Rolli, M.D., to its Board of Directors and the intention to propose the ratification of her appointment at ERYTECH’s next General Meeting of Shareholders. Dr. Rolli has more than 15 years of experience in the global biopharmaceutical and biotechnology industry, including in both Europe and the United States. Dr. Rolli’s appointment follows the resignation of Allene Diaz, who resigned from the Board effective September 30, 2019.
ERYTECH to Host Fourth Quarter and Full Year 2019 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2019 conference call and webcast on Tuesday, March 17, 2020, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present a corporate update at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020 in Boston, MA.
ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that it has entered into a strategic partnership with the German Red Cross Blood Donor Service Baden-Württemberg-Hessen (GRCBDS) to complement the existing alliance with the French Blood bank (EFS) for the supply of donor red blood cells to manufacture its product candidates, including eryaspase, in Europe.
ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the presentation of a Trial in Progress Poster for the ongoing Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium in San Francisco.
ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer
First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors
ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in the European Journal of Cancer.
ERYTECH to Present at Jefferies 2019 HealthCare Conference in London
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer of ERYTECH, is scheduled to present at the Jefferies 2019 Healthcare Conference in London on November 20, 2019. The presentation starts at 4:40 p.m. GMT/11:40 a.m. EST and will be webcast.
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019
Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET.
- TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer:
- positive safety review by independent data monitoring committee
- opened for patient enrollment in the United States
- first U.S. clinical sites activated
- Princeton manufacturing facility ready for production of clinical batches
- Cash position of €81.9 million ($89.2 million) at the end of September
ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2019 conference call and webcast on Friday, November 8, 2019, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer.
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019
Conference call and webcast on Wednesday, September 18 at 2:30 pm CET/8:30 am EDT
- TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on plan
- Immune modulation collaboration entered into with SQZ Biotechnologies
- Board strengthened with appointment of Dr. Jean Paul Kress as Chairman
- Cash position of €94.5 million ($107.5 million) at the end of June
ERYTECH to Host Second Quarter 2019 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2019 conference call and webcast on Wednesday, September 18, 2019, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019.
ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019
ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2, evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC).
ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it has entered into an agreement with SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel RBC-based therapeutics for immune modulation.
ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility
Inauguration event held last week to officially open 30,000 sq. ft GMP manufacturing facility constructed in Princeton, NJ to produce lead product candidate eryaspase in the United States.
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the availability of the documents for its Annual General Meeting to be held on June 21, 2019.
ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells. The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer.
ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provides a business update and reports its financial results for the quarter ended March 31, 2019.
ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that the Board of Directors will propose the appointment of Jean-Paul Kress as a Director at the Annual General Meeting on June 21, 2019, with a view to appointing him as Chairman of the Board of Directors. Dr. Kress possesses over 25 years’ experience as a senior executive in international biotech and pharma groups.
ERYTECH to Host on May 7, 2019 First Quarter Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2019 first quarter conference call and webcast on Tuesday, May 7, 2019, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced today the presentation of a poster highlighting new preclinical results for the Company’s second product candidate, erymethionase, at the 2019 American Association of Cancer Research (AACR) annual meeting held in Atlanta, Georgia. The poster (Abstract 2258) is available at www.erytech.com.
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2018
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the year ended December 31, 2018.
ERYTECH Presents Findings at European Red Cell Research Society Meeting
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that an oral presentation entitled “Comprehensive proteomic profiling of erythrocytes following hypotonic dialysis-based drug encapsulation process“ will be presented today at the 22nd meeting of the European Red Cell Research Society (ERCS) in Ascona, Switzerland. A poster highlighting the results of this work will also be presented at the ERCS Meeting and will be available on the Company’s website at www.erytech.com after March 11, 2019.
ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that Gil Beyen, the company’s chairman and chief executive officer, will present at the Cowen & Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 at The Marriott Copley Place, in Boston, MA.
Conference Details:
- Conference: Cowen and Company 39th Annual Health Care Conference
- Date: March 13, 2019
- Presentation Time: 8:40am EDT / 13:40 CET
ERYTECH to Host Fourth Quarter and Full Year 2018 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2018 conference call and webcast on Tuesday, March 12, 2019, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled “TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)” will be presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in San Francisco. The poster (Abstract # TPS471) will be available at www.erytech.com after presentation at the conference.
ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research.
ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended September 30, 2018.
ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a Key Opinion Leader (KOL) breakfast symposium, focused on the potential of eryaspase to treat patients with pancreatic cancer and triple-negative breast cancer, on Wednesday, November 7, 2018 from 8:00 A.M. – 11:00 A.M. ET in New York City.
ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference
ERYTECH Pharma today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15th, 2017 at the Waldorf Hilton Hotel (Aldwych) in London, UK.
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer.
ERYTECH to Attend Upcoming Investor Conferences
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2018.
ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended June 30, 2018.
ERYTECH to Host Second Quarter 2018 Conference Call and Bussiness Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second quarter 2018 conference call and webcast on Tuesday, September 11, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:
ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications. The company also announced that it plans to cease its development program for eryaspase in acute lymphoblastic leukemia (ALL), including the withdrawal of its previously submitted MAA for eryaspase for the treatment of relapsed and refractory ALL.
ERYTECH to Present at JMP Securities Life Science Conference
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City.
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden.
General Meeting to be held on June 28, 2018 and Availability of Related Materials
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the availability of documents for its Annual General Meeting, to be held on June 28, 2018.
ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois.
ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at The Grand Hyatt, in New York City.
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended March 31, 2018
ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product marketing and sales across small biotech start-ups and multi-national pharmaceutical companies.
ERYTECH to Host First Quarter 2018 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC).
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018
Lyon (France), April 12, 2018 – ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present full results from its U.S. Phase I trial evaluating eryaspase (GRASPA) in combination with chemotherapy for the treatment of acute lymphoblastic leukemia (ALL) and pre-clinical data on the erymethionase program at the upcoming American Association for Cancer Research Annual Meeting, being held April 14-18, 2018 in Chicago, Illinois.
ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at The Marriott Copley Place, in Boston, MA.
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017
ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the year ended December 31, 2017.
ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2017 conference call and webcast on Tuesday, March 13, 2018, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
LYON, France – February 13, 2018 – ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the selection of Triple Negative Breast Cancer as the next target indication for broadening the scope of eryaspase (GRASPA®) development in solid tumors.
ERYTECH to Present at the 2018 BIO CEO & Investor Conference
LYON, France – February 8, 2018 – ERYTECH Pharma (Euronext Paris: ERYP, Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference, being held February 12-13, 2018 at the New York Marriott Marquis in New York City.
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) (“ERYTECH”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced topline results from its Phase 2b clinical study evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML).
ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
ERYTECH Pharma today announced the initial closing of its previously announced global offering to specified categories of investors of an aggregate of 5,374,033 new ordinary shares, comprising an offer of 4,686,106 ordinary shares in the form of American Depositary Shares, each representing one ordinary share (“ADSs”), in the United States at an offering price of $23.26 per ADS and a concurrent private placement in Europe (including France) and other countries outside of the United States and Canada of 687,927 ordinary shares at an offering price of €20.00 per ordinary share. In addition, the underwriters for the global offering have exercised in full their option to purchase at the same price 702,915 additional ADSs and 103,189 additional ordinary shares in the global offering, with the additional closing expected to occur on November 16, 2017. Following the additional closing, aggregate net proceeds to ERYTECH, after deducting underwriting commissions and estimated offering expenses payable by ERYTECH, will be approximately $130 million. All of the securities sold in the global offering were offered by ERYTECH.
ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference
ERYTECH Pharma today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15th, 2017 at the Waldorf Hilton Hotel (Aldwych) in London, UK.
ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017
ERYTECH Pharma today announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
Erytech announces trading resumption of its ordinary shares on Euronext Paris
ERYTECH Pharma announces trading resumption of its ordinary shares on Euronext Paris as from 4:00pm CET.
Erytech announces trading suspension of its ordinary shares on Euronext Paris
Trading in the ordinary shares of ERYTECH Pharma, was suspended at the request of the Company on November 10, 2017 from 9:00 am CET in connection with its previously announced global offering in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Select Market.
ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update
ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2017.
ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing
ERYTECH today announced its intention to issue and sell, subject to market and other conditions, approximately $125 million corresponding to an aggregate of up to 5,319,148 of its ordinary shares in a global offering to specified categories of investors, including an offer of American Depositary Shares, each representing one ordinary share (“ADSs”), in the United States and a concurrent private placement of ordinary shares in Europe (including France) and other countries outside of the United States and Canada (together, the “Global Offering”). ERYTECH intends to grant the underwriters a 30-day over-allotment option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.
ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
ERYTECH today announced that it has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). The MAA resubmission includes the data from ERYTECH’s GRASPALL 2009-06 Phase 2/3 clinical trial in children and adults with R/R ALL as well as additional data to address the outstanding questions of the Committee for Medicinal Products for Human Use (CHMP) of the EMA.
ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States
ERYTECH today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American Depositary Shares (“ADSs”), each representing one ordinary share, in the United States and a concurrent private placement of its ordinary shares in Europe and other countries outside of the United States and Canada (together, the “Global Offering”). All securities to be sold in the Global Offering will be offered by ERYTECH. The number of securities to be sold and the price range for the proposed Global Offering have not yet been determined. ERYTECH has applied to list its ADSs on the NASDAQ Global Market under the ticker symbol “ERYP.” The ordinary shares are listed on Euronext Paris under the symbol “ERYP.”
ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL
ERYTECH today announced the determination of the recommended pivotal Phase 3 dosing from its U.S. Phase 1 dose escalation study with eryaspase (GRASPA®) in first line treatment of adult ALL patients.
ERYTECH to Present at Morgan Stanley Global Healthcare Conference
ERYTECH today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017 at the Grand Hyatt Hotel in New York City..
ERYTECH Reports First Half 2017 Financial Results and Provides Business Update
ERYTECH today provided a business update and reported its financial results for the six-month period ended June 30, 2017.
ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
ERYTECH today announced the presentation of the full data from its Phase 2b study evaluating eryaspase (GRASPA®) in combination with chemotherapy for the treatment of metastatic pancreatic cancer. The open-label, multi-center, randomized Phase 2b clinical study met its co-primary endpoints and demonstrated significant improvement in both overall survival (OS) and progression-free survival (PFS). The results will be presented during the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid.
ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
ERYTECH today announced that it will host a Second Quarter 2017 conference call and webcast on Tuesday, September 12, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
ERYTECH to Present Pre-Clinical Data at the 13th International Congress of Inborn Errors of Metabolism
ERYTECH today announced that two abstracts on its preclinical erymethionase and eryminase programs were accepted for poster presentation at the 13th International Congress of Inborn Errors of Metabolism (ICIEM), being held September 5 – 8, 2017 in Rio De Janeiro, Brazil.
ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017
ERYTECH today announced that it will present the full data from its Phase 2b trial evaluating eryaspase for the treatment of metastatic pancreatic cancer at the upcoming European Society for Medical Oncology Annual Meeting, being held September 8 – 12, 2017 in Madrid, Spain.
ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders
ERYTECH today announced that it has entered into a research collaboration with Queen’s University in Canada to advance the preclinical development of ERYTECH’s eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism. The collaboration will leverage the expertise of Queen’s University and ERYTECH’s ERYCAPS platform technology with the goal of generating in vivo proof-of-concept data in an arginase-1 deficiency animal model.
ERYTECH PHARMA : ANNUAL GENERAL MEETING OF JUNE 27, 2017
ERYTECH announced today the modalities for making available the documents for the Annual General Meeting of June 27, 2017.
ERYTECH Provides Business Update and Financial Highlights for Q1 2017
ERYTECH today provided a financial and business update for the first quarter of 2017 ended March 31, 2017.
Erytech to Hold Q1 2017 Business Update Conference Call on May 19th, 2017
ERYTECH today announced that it will release its financial results and business update for the quarter ended March 31, 2017 on Thursday, May 18, 2017 after the close of trading on the Euronext Paris.
ERYTECH TO RAISE €70.5 MILLION IN A PRIVATE PLACEMENT TO U.S. AND EUROPEAN INVESTORS
ERYTECH announces today that, in connection with the anticipated completion of a capital increase of 3,000,000 new ordinary shares reserved, it has obtained commitments from qualified investors in the United States and in Europe to purchase ordinary shares of the Company in a private placement reserved for a specified category of investors described below (the “Reserved Offering”). Total gross proceeds from the Reserved Offering placement are expected to be €70.5 million, before deducting fees and expenses. Jefferies International Limited acted as Sole Global Coordinator and acted together with Cowen and Company, LLC and Oddo & Cie as Joint Bookrunners in the Reserved Offering.
ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
ERYTECH today announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study will take place in seven Nordic countries and be conducted in collaboration with the Nordic Society of Pediatric Hematology and Oncology (NOPHO).
ERYTECH makes its 2016 Reference Document available
ERYTECH today announced that it had filed on March 31, 2017 with the “Autorité des Marchés Financiers (AMF)”, its 2016 Reference Document, including the management report and the annual financial report.
ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer
ERYTECH today announced positive topline results from its Phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA®), in combination with chemotherapy for the treatment of second-line metastatic pancreatic cancer. The multicenter, randomized Phase 2b study met its prespecified co-primary endpoints, and showed significant improvement in both progression-free survival (PFS) and overall survival (OS) in patients treated with eryaspase combined with chemotherapy compared to chemotherapy alone.
ERYTECH collaborates with Fox Chase Cancer Center to advance its platform in the field of rare metabolic disorders
ERYTECH today that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for homocystinuria, a rare and severe metabolic disorder of methionine metabolism. The collaboration will leverage FCCC’s world-class expertise to generate in vivo proof-of-concept data with erymethionase in a homocystinuria animal model.
ERYTECH Presents New Preclinical Anti-Tumor Data on erymethionase at AACR 2017
ERYTECH today announced the presentation of new anti-tumor data supporting the Company’s preclinical product erymethionase (ERY-MET) at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1 – 5, 2017 in Washington, D.C.
ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings
ERYTECH today announced the presentation of encouraging preclinical data supporting the Company’s ERYMMUNE program at two upcoming immunotherapy medical meetings, World ADOPT Summit 2017 and 10th Symposium of Vaccinology. The World ADOPT Summit 2017 is being held March 7-9, 2017 at the Cavendish Conference Centre in London, U.K., and the 10th Symposium of Vaccinology is being held March 20-21, 2017 at the Université Lumière Lyon II in Lyon, France. In conjunction with the Symposium of Vaccinology, ERYTECH will also share the results with the members of the French Society of Immunology.
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2016
ERYTECH today provided a business update and reported its financial results for the year ended December 31, 2016.
ERYTECH to hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
ERYTECH today announced that it will release its financial results and business update for the year ended December 31, 2016 on Thursday, March 02, 2017 after the close of trading on the Euronext Paris.
ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
ERYTECH today announced new data supporting the second Company’s product candidate ERY-MET will be presented at the 2017 Gastrointestinal Cancers Symposium co-sponsored by the American Society of Clinical Oncology (ASCO GI), being held January 19 – 21, 2017 in San Francisco, California.
ERYTECH RAISES €10 MILLION IN PRIVATE PLACEMENT WITH U.S. AND EUROPEAN INVESTORS
ERYTECH today announced the closing of a private placement of 793,877 ordinary shares to qualified investors in the United States and Europe for total gross proceeds of approximately €10 million.
ERYTECH Presents New Data on GRASPA’s Mechanism of Action at ASH Annual Meeting
ERYTECH today announced the presentation of promising preliminary data for the Company’s lead product candidate, eryaspase, also known as ERY-ASP or under the trade name GRASPA®, at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.
ERYTECH Announces Withdrawal of its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission
ERYTECH today announced its decision to withdraw the current MAA for GRASPA for the treatment of acute lymphoblastic leukemia (ALL). The Company determined that the time allowed in the CHMP procedure was not sufficient to provide the additional data requested in the CHMP’s Day 180 List of Outstanding Issues (LOI). The Company intends to resubmit an MAA around mid-2017.
ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016
ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2016.
ERYTECH Strengthens Executive Leadership Team with Appointments of Chief Scientific Officer and Chief Business Officer
ERYTECH today announced the appointments of Dr. Alexander Scheer, Ph.D. as the company’s Chief Scientific Officer and Jean-Sébastien Cleiftie, as Chief Business Officer.
ERYTECH to Hold Q3 2016 Business Update Conference Call on November 4th, 2016
ERYTECH today announced that it will release its financial results and business update for the quarter ended September 30, 2016 on Thursday, November 03, 2016 after the close of trading on the Euronext Paris.
ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer
ERYTECH Pharma today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer.
ERYTECH Reports Business and Financial Update for the First Half of 2016
ERYTECH Pharma today provided a business update and reported its financial results for the six month period ended June 30, 2016.
ERYTECH Appoints Allene M. Diaz to its Board of Directors
ERYTECH Pharma today announced the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur).
ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia
ERYTECH Pharma today announced that it has reached full patient enrollment in the Phase 2b trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of acute myeloid leukemia (AML).
ERYTECH PHARMA : ANNUAL GENERAL MEETING OF JUNE 24, 2016
Erytech announced today the modalities for making available the documents for the Annual General Meeting of June 24, 2016.
ERYTECH Provides Business and Financial Highlights for First Quarter 2016
Erytech today provided a business update and reported financial results for its first quarter ended March 31, 2016.
Erytech to Hold Q1 2016 Business Update Conference Call on May 11th, 2016
Erytech today announced that it will release its financial results and business update for the quarter ended March 31, 2016 on Tuesday, May 10, 2016 after the close of trading on the Euronext Paris.
ERYTECH makes its 2015 Reference Document available
ERYTECH today announced that it had filed on April 29, 2016 with the “Autorité des Marchés Financiers (AMF)”, its 2015 Reference Document, including the management report and the annual financial report.
ERYTECH to Present Two Posters at AACR
ERYTECH today announced that it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20, 2016 in New Orleans, LA, USA.
ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS Immunotherapy Technology
ERYTECH today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 12/672,094 entitled “Composition and Therapeutic Anti-tumor Vaccine.”
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015
Conference call and webcast on Wednesday, February 24th at 15:00 pm CET/09:00 am EST
Erytech Announces 2016 Financial Calendar
ERYTECH today published its financial calendar for 2016.
Erytech to Present at Upcoming Investor Conferences
ERYTECH will present at the 18th Annual BIO CEO and Investor Conference being held February 8-9, 2016 and the Leerink Partners 5th Annual Global Healthcare Conference being held February 10-11, 2016. Both conferences are being held at the Waldorf Astoria Hotel in New York.
ERYTECH Reports Financial Highlights for Q4 2015
ERYTECH reports revenue and cash balance for the fourth quarter of 2015.
ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia
ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB1) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.
ERYTECH Announces Management Change
ERYTECH today announced that Yann Godfrin will be leaving the company to pursue new entrepreneurial projects.
ERYTECH wins the European Small and Mid-Cap Award in the Most Innovative Newcomer category
ERYTECH announced today that it received yesterday evening the “European Small and Mid-Cap” award in the “Most Innovative Newcomer” category by the Federation of European Stock Exchanges.
ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting
ERYTECH announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA that add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL).
ERYTECH raises approximately €25.4 million in a private placement
ERYTECH today announces the closing of a private placement of 940,000 ordinary shares to qualified investors in the United States and Europe for a total amount of approximately €25.4 million.
ERYTECH to raise approximately € 25.4 million in a private placement of ordinary shares to European and U.S. institutional investors
ERYTECH today announces the pricing of a private placement of 940,000 ordinary shares to qualified investors in the United States and Europe for a total amount subscribed of approximately € 25.4 million. This private placement was conducted by Jefferies International Limited, Leerink Partners LLC and Bryan Garnier & Co. Limited, acting as placement agents and LifeSci Capital LLC, acting as co-manager.
ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region
ERYTECH announced today that it received Deloitte Technology Fast 50 award in the “Promising Biotech” category for France’s Grand Rhone-Alpes region.
ERYTECH announces data presentations at the American Society of Hematology 57th Annual Meeting
ERYTECH announces the upcoming presentation of three abstracts at the American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida, USA from December 5-8, 2015.
ERYTECH reports financial highlights for Q3 2015
ERYTECH reports cash balance and revenues for the third quarter of 2015.
ERYTECH announces publication of two articles describing clinical results with eryaspase/GRASPA
ERYTECH announces the publication of two peer-reviewed manuscripts describing clinical results obtained with eryaspase/GRASPA®.
ERYTECH provides business update and financial results for the first half of 2015
ERYTECH provides a business update and reports its financial results for the six-month period ending June 30, 2015.
ERYTECH strengthens its intellectual property position with the issuance of United States patent for erythrocytes containing arginine deiminase
ERYTECH announces the issuance of a new patent in the United States.
ERYTECH to host a webcast on September 29, 2015 for its 2015 half-year results
ERYTECH will announce its half-year results for 2015 on Monday September 28, 2015, after market close, and hold a presentation webcast on the September 29, 2015 at 2:30 pm CET / 8:30 am EDT.
ERYTECH submits EMA Marketing Authorization Application for GRASPA to treat acute lymphoblastic leukemia
ERYTECH announces today the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for eryaspase (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL).
ERYTECH appoints Eric Soyer as Chief Financial and Chief Operating Officer
ERYTECH announces the appointment of Eric Soyer as Chief Financial and Chief Operating Officer (CFO/COO).
ERYTECH announces plans to conduct registered initial public offering in the United States
ERYTECH today announced that the Company plans to conduct a registered initial public offering in the United States.
ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer
ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.
ERYTECH appoints Dr. Iman El-Hariry as Chief Medical Officer
ERYTECH announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.
ERYTECH reports financial highlights for Q2 2015
ERYTECH reports cash balance and revenues for the second quarter of 2015.
ERYTECH announces two positive DSMB reviews
ERYTECH announces positive safety reviews after the completion of the first cohort in the company’s US Phase I study with eryaspase in Acute Lymphoblastic Leukemia (ALL), and following the treatment of the first three patients with eryaspase in combination with Folfox in its Phase II study in pancreatic cancer.
ERYTECH announces presentation and webcast at the Jefferies 2015 Healthcare Conference
ERYTECH announces that Gil Beyen, Chairman & CEO of the company, will present a company overview at the Jefferies 2015 HealthCare Conference in New York on June 4 at 9:00 am Eastern Time.
ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO
ERYTECH reported complete Phase III results of its pivotal program with GRASPA® in Acute Lymphoblastic Leukemia (ALL) and presented the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). During an investigator meeting ERYTECH also presented the progress and plans on other development programs.
ERYTECH announces oral presentations of GRASPA® Phase III results at ASCO and EHA annual meetings
ERYTECH announces that the data related to GRASPA® Phase 3 pivotal program in Acute Lymphoblastic Leukemia (ALL) will be the subject of oral presentations at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2, Chicago, USA, and at the 20th Congress of European Hematology, June 11 – 14, Vienna, Austria. A poster on the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) will also be presented at ASCO.
ERYTECH reports financial highlights for Q1 2015
ERYTECH reports cash balance and revenues for the first quarter of 2015.
ERYTECH announces positive DSMB annual review of its Expanded Access Program in ALL
ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia (ALL) and recommended continuation of the program without modification.
ERYTECH receives the EnterNext Tech 40 Label
ERYTECH has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index.
ERYTECH strengthens its intellectual property position in the US
ERYTECH announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent.
ERYTECH provides business update and financial results for the full year 2014
ERYTECH provides a business update and reports its financial results for the period ending December 31, 2014.
ERYTECH appoints new independent board member
ERYTECH announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June.
ERYTECH announces three data presentations at the 2015 AACR Annual Meeting
ERYTECH announces the upcoming presentation of three abstracts, at the American Association for Cancer Research (AACR) taking place in Philadelphia, PA, USA from 18 to 22 April 2015.
ERYTECH reports financial highlights for Q4 2014 and updates on upcoming milestones
ERYTECH reports revenues and cash balance for the fourth quarter of 2014 and provides an update on upcoming milestones.
ERYTECH announces ADR Level 1 listing in the US
ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.
ERYTECH announces management change
ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests.
ERYTECH reports additional positive Phase III results from clinical study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia
ERYTECH reports additional positive Phase III results from the pivotal study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia.
ERYTECH to present at Jefferies Global Healthcare Conference
ERYTECH will be presenting at Jefferies Global Healthcare Conference in London next week.
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH
ERYTECH announces the presentation of four case studies with GRASPA® in an expanded access program at the 56th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2014, in San Francisco, CA.
ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments
ERYTECH announces today the successful completion of a capital increase for a total amount of €30 million.
ERYTECH announces granting of new patent in the United States
ERYTECH announces the granting of a new patent in the field of asparaginase in the United States.
ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014
ERYTECH won EuropaBio’s Most Innovative European Biotech SME Award 2014.
ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia
ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.
ERYTECH business update and financial results for the first half of 2014
ERYTECH provides a business update and reports its financial results for the period ending June 30, 2014.
ERYTECH announces second positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia
ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) and unanimously recommended continuation of the trial without modification.
ERYTECH announces enrollment of first patient in Phase II study of eryaspase in pancreatic cancer
ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer.
ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States
ERYTECH announces the enrollment of the first patient in its Phase I/II study with eryaspase in Acute Lymphoblastic Leukemia in the United States of America.
ERYTECH provides financial update for Q2 2014
ERYTECH provides a financial update for the second quarter of 2014.
ERYTECH appoints two new independent board members
ERYTECH announces it has appointed Dr Martine George and Mrs Hilde Windels as new independent members to its board of directors.
ERYTECH strengthens its intellectual property portfolio
ERYTECH announces the granting of two key patents for its core product eryaspase.
ERYTECH provides financial update for Q1 2014
ERYTECH provides a financial update for the first quarter of 2014.
ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer
ERYTECH announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.
ERYTECH provides business update and financial results for the full year 2013
ERYTECH provides a business update and reports its financial results for the period ending December 31, 2013.
ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio
ERYTECH announces the addition of a new product development candidate, erymethionase, to the company’s Cancer Metabolism product pipeline.
ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia
ERYTECH announces that its lead product GRASPA®/eryasp1 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
ERYTECH welcomes new US and European investors
ERYTECH was informed today that certain of its historical institutional investors have sold part of their holdings to new specialized life sciences investors in the United States and in Europe.
ERYTECH PHARMA launches a subscription of BSPCE warrants reserved for its main executives
ERYTECH launch a subscription of BSPCE reserved for its main executives.
ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013
ERYTECH held its first Investor R&D day and provides a financial and business update for the fourth quarter of 2013.
ERYTECH announces its financial calendar for 2014
ERYTECH announces its financial calendar for 2014
ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML
ERYTECH announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain.
ERYTECH positions its lead product in solid tumors and launches a Phase II clinical study in pancreatic cancer
ERYTECH provides an update on its development plans to broaden the scope of its lead product eryaspase into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.
ERYTECH announces the decision of USPTO to extend the additional exclusivity period of its core process patent to almost 4 years
ERYTECH announces its received final notification of allowance for the granting of its core process patent in the United States in which the term of exclusivity has been further extended from two to almost four years
ERYTECH announces two presentations at 55th ASH annual meeting and exposition in New Orleans
ERYTECH announces that data related to the Company’s lead product GRASPA® will be the subject of two poster presentations at the 55th American Society of Hematology (ASH) Annual Meeting and Exhibition on December 7 and 8 in New Orleans, USA.
ERYTECH announces positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia
ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its first assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) study and unanimously recommended continuation of the trial without modification.
ERYTECH provides financial update for Q3 2013
ERYTECH announces today its cash position and its revenues for the third quarter of 2013.
ERYTECH announces the granting of its core process patent in the United States with two additional years of exclusivity
ERYTECH announces it received notification of allowance for the granting of its core process patent in the United States with two additional years of exclusivity in the United States.
ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia
ERYTECH announces the completion of the enrollment of patients in its pivotal Phase III study in Acute Lymphoblastic Leukemia (ALL).
ERYTECH business update and financial results for the first half of 2013
ERYTECH provides a business update and reports its financial results for the period ending June 30, 2013.
ERYTECH provides financial update for Q2 2013
ERYTECH announced today its cash position and its revenues for the second quarter of 2013.
ERYTECH announces fast take-off of its Phase IIb study in Acute Myeloid Leukemia
ERYTECH announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia (AML).
ERYTECH provides financial update for Q1 2013
ERYTECH announced today its cash position and its revenues for first quarter 2013.
ERYTECH to present at upcoming investor conferences
ERYTECH announced today that in May and June the company will present at several visible investor events in Europe and the U.S following its successful IPO on April, 2013. As a public company ERYTECH is committed to actively engage with investors and the financial community.
ERYTECH’s IPO a remarkable success, raising €17.7 million
ERYTECH today announced the success of its IPO in compartment C of the NYSE Euronext regulated market in Paris, raising more than the target amount of €15 million.
ERYTECH announces its IPO on NYSE Euronext Paris regulated market
ERYTECH today announces that the French market regulator Autorité des Marchés Financiers (AMF) granted its visa n°13-166 on April 17, 2013 for the prospectus relative to the listing of ERYTECH shares on the NYSE Euronext regulated market in Paris.
ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.
ERYTECH announced today that it has received clearance of its Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its product ERYASP®, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia (ALL).
ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe
Erytech Pharma announced today that it has entered into a definitive agreement and Orphan Europe, part of the Recordati Group, granting Orphan Europe exclusive rights for the commercialization and distribution of GRASPA® in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe.
ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.
ERYTECH Pharma announces the oral presentation of positive Phase II clinical trial results in Acute Lymphoblastic Leukemia.
ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency
Erytech Pharma announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease.
ERYTECH PHARMA receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer
ERYTECH Pharma is pleased to announce that it received a total of € 6.95 million in support from the Strategic Industrial Innovation program of the French public organization OSEO to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy).
ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer
ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®.
ERYTECH Pharma to partner with Teva for long term distribution agreement in Israel
ERYTECH Pharma is pleased to announce it has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of Graspa®, the company‟s lead product, in Israel.
ERYTECH Pharma to present promising results for the treatment of Sickle Cell Disease
ERYTECH Pharma will in the near future present their promising results obtained with the GR-ARA1 project for the treatment of sickle cell disease.
ERYTECH Pharma announces appointment of Marc Beer to the Supervisory Board
ERYTECH Pharma is pleased to welcome Marc Beer as a new board member.